The Retinoic Acid Pathway Therapeutics Market Size is predicted to grow at an 7.4% CAGR during the forecast period for 2024-2031.
The retinoic acid pathway therapeutics market is a fast-emerging field dealing with the discovery and application of retinoic acid, which is a vitamin A metabolite, in a variety of medical therapies. RA plays an important role in biologic processes, such as cell differentiation, growth regulation, and apoptosis. There is extensive interest in oncology in the treatment of cancers that include acute promyelocytic leukemia and cutaneous T-cell lymphoma, wherein it induces differentiation of cancer cells. RA has been widely used in dermatology for the treatment of acne, psoriasis, and skin aging, mainly because it enhances cell turnover of the skin and inhibits inflammation. Currently, RA is also being researched as a compound for regenerative medicine and the treatment of neurodegenerative diseases.
Since this market is experiencing an upward trend, several reasons have motivated it. First, the increasing incidence of skin-related conditions and cancers in the global economy is on the rise. Moreover, rising awareness of the therapeutic benefits of retinoids has been growing. Also, research into novel formulations and delivery systems that enhance efficacy while minimizing side effects is yet another major force behind the growth of the RA therapeutics market. In fact, a strong pipeline of clinical trials involving new retinoid compounds being explored for their potential across various therapeutic areas is an excellent example of where innovation and clinical use converge perfectly in the RA therapeutics market.
The retinoic acid pathway therapeutics market is segmented by product type, application, route of administration, distribution channel, end-user. By product type the market is segmented into retinoic acid receptor agonists (RAR Agonists), retinoid X receptor agonists (RXR agonists), RAR and RXR dual agonists, others (novel/next-generation retinoic acid derivatives). By application the market is segmented into cancer treatment, dermatological disorders, autoimmune disorders, others (e.g., neurological disorders, respiratory diseases). Cancer treatment is sub segmented into acute promyelocytic leukemia, skin cancer, and other cancer treatment. Dermatological Disorders is sub segmented into acne, psoriasis, eczema, and others.
Retinoic Acid Receptor Agonists are the most dominant drugs in retinoic acid pathway therapeutics market as they have major roles in cancer therapy and cellular differentiation. RARs mediate gene expression necessary for cell growth, differentiation, and apoptosis through retinoic acid. Retinoic acid binding to the receptor causes RAR to heterodimerize with retinoid X receptors (RXRs). The complex then interacts with the elements of retinoic acid response elements (RAREs) to modulate gene transcription. All-trans-retinoic acid (ATRA) is a potent RAR agonist. APL cells undergo differentiation when treated with this drug, resulting in very impressive clinical success. Beyond APL, other RAR agonists are currently being explored in clinical trials for other cancers such as breast and prostate, and the regulation of tumor suppressor genes makes them promising therapeutic agents.
Recently, the retinoic acid pathway therapeutics market for cancer treatment has been experiencing rapid growth, likely due to the increasing recognition of retinoic acid and its derivatives as promising therapies for various cancers, including acute promyelocytic leukemia (APL), breast cancer, and prostate cancer. According to the National Cancer Institute, the incidence of new prostate cancer cases is 116.5 per 100,000 men annually, with a death rate of 19.0 per 100,000 men, highlighting the urgent need for effective treatment options in this area. Contributing to this market growth are factors such as the efficacy of all-trans retinoic acid (ATRA) in inducing differentiation in cancer cells, particularly in patients with APL. Additionally, ongoing research is revealing broader roles for retinoic acid in cancer progression, including its potential as an immune checkpoint inhibitor, which could enhance the effectiveness of existing therapies.
Europe is currently dominating the market of retinoic acid pathway therapeutics in the wake of increased expansions in the cosmetics industry and increases awareness toward healthiness of the skin. The cosmetics industry has been excelling in the region with newly designed products for skincare and special treatments, while increased concerns for skin conditions like cancer and negativity of UV exposure have uplifted the demand for retinoid-based products in Europe. Its major industrial presence in the form of BASF SE and DSM Nutritional Products enhances the market. Therapeutic applications in Europe: The use of retinoic acid has gained popularity in Europe also, right from beyond cosmetics, all the way to cancer treatments in the form of all-transretinoic acid (ATRA) for acute promyelocytic leukemia (APL), and in dermatology in conditions such as acne and psoriasis.
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 7.4% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product Type, By Application, By Route of Administration, By Distribution Channel, By End-user |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
|
Competitive Landscape |
Roche Holding AG, Bristol-Myers Squibb, Allergan (AbbVie), Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Valeant Pharmaceuticals (Bausch Health Companies Inc.), Mylan N.V., TetraLogic Pharmaceuticals, Ortho Dermatologics, Kayothera, Ionis Pharmaceuticals, TetraLogic Pharmaceuticals, Dermira (Eli Lilly and Company), Hovione, Phosphagenics Limited, Ligand Pharmaceuticals, Aclaris Therapeutics, Orphazyme A/S , Cipla Ltd. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Retinoic Acid Pathway Therapeutics Market Snapshot
Chapter 4. Global Retinoic Acid Pathway Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Retinoic Acid Pathway Therapeutics Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on RETINOIC ACID PATHWAY THERAPEUTICS MARKET Industry Trends
Chapter 5. Retinoic Acid Pathway Therapeutics Market Segmentation 1: By Product Type, Estimates & Trend Analysis
5.1. Market Share by Product Type, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Product Type:
5.2.1. Retinoic Acid Receptor Agonists (RAR Agonists)
5.2.2. Retinoid X Receptor Agonists (RXR Agonists)
5.2.3. RAR and RXR Dual Agonists
5.2.4. Others (Novel/Next-Generation Retinoic Acid Derivatives)
Chapter 6. Retinoic Acid Pathway Therapeutics Market Segmentation 2: By Product Type, Estimates & Trend Analysis
6.1. Market Share by Application, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Application:
6.2.1. Cancer Treatment
6.2.1.1. Acute Promyelocytic Leukemia
6.2.1.2. Skin Cancer
6.2.1.3. Other Cancer Treatment
6.2.2. Dermatological Disorders
6.2.2.1. Acne
6.2.2.2. Psoriasis
6.2.2.3. Eczema
6.2.2.4. Others
6.2.3. Autoimmune Disorders
6.2.4. Others (e.g., Neurological Disorders, Respiratory Diseases)
Chapter 7. Retinoic Acid Pathway Therapeutics Market Segmentation 3: By Route of Administration, Estimates & Trend Analysis
7.1. Market Share by Route of Administration, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Route of Administration:
7.2.1. Oral
7.2.2. Topical
7.2.3. Intravenous
7.2.4. Others
Chapter 8. Retinoic Acid Pathway Therapeutics Market Segmentation 4: By Distribution Channel, Estimates & Trend Analysis
8.1. Market Share by Distribution Channel, 2023 & 2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Distribution Channel:
8.2.1. Rx
8.2.2. OTC
Chapter 9. Retinoic Acid Pathway Therapeutics Market Segmentation 4: By End-users, Estimates & Trend Analysis
9.1. Market Share by End-users, 2023 & 2031
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following End-users:
9.2.1. Hospitals and Clinics
9.2.2. Retail Pharmacies
9.2.3. Online Pharmacies
9.2.4. Research Institutes
Chapter 10. Retinoic Acid Pathway Therapeutics Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global Retinoic Acid Pathway Therapeutics Market, Regional Snapshot 2023 & 2031
10.2. North America
10.2.1. North America Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2019-2031
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2019-2031
10.2.3. North America Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
10.2.4. North America Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2019-2031
10.2.5. North America Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
10.2.6. North America Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End-users, 2019-2031
10.3. Europe
10.3.1. Europe Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2019-2031
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2019-2031
10.3.3. Europe Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
10.3.4. Europe Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2019-2031
10.3.5. Europe Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
10.3.6. Europe Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End-users, 2019-2031
10.4. Asia Pacific
10.4.1. Asia Pacific Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2019-2031
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2019-2031
10.4.3. Asia Pacific Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
10.4.4. Asia Pacific Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts By Route of Administration, 2019-2031
10.4.5. Asia Pacific Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
10.4.6. Asia Pacific Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End-users, 2019-2031
10.5. Latin America
10.5.1. Latin America Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2019-2031
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2019-2031
10.5.3. Latin America Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
10.5.4. Latin America Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2019-2031
10.5.5. Latin America Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
10.5.6. Latin America Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End-users, 2019-2031
10.6. Middle East & Africa
10.6.1. Middle East & Africa Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2019-2031
10.6.3. Middle East & Africa Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
10.6.4. Middle East & Africa Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2019-2031
10.6.5. Middle East & Africa Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
10.6.6. Middle East & Africa Retinoic Acid Pathway Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End-users, 2019-2031
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Roche Holding AG
11.2.1.1. Business Overview
11.2.1.2. Key Product/Service Route of Administration
11.2.1.3. Financial PerProduct Typeance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. Bristol-Myers Squibb
11.2.3. Allergan (AbbVie)
11.2.4. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
11.2.5. Teva Pharmaceutical Industries Ltd.
11.2.6. Sun Pharmaceutical Industries Ltd.
11.2.7. Valeant Pharmaceuticals (Bausch Health Companies Inc.)
11.2.8. Mylan N.V.
11.2.9. TetraLogic Pharmaceuticals
11.2.10. Ortho Dermatologics
11.2.11. Kayothera
11.2.12. Ionis Pharmaceuticals
11.2.13. TetraLogic Pharmaceuticals
11.2.14. Dermira (Eli Lilly and Company)
11.2.15. Hovione
11.2.16. Phosphagenics Limited
11.2.17. Ligand Pharmaceuticals
11.2.18. Aclaris Therapeutics
11.2.19. Orphazyme A/S
11.2.20. Cipla Ltd.
11.2.21. Other Prominent Players
The Retinoic Acid Pathway Therapeutics Market by Product Type -
The Retinoic Acid Pathway Therapeutics Market by Application -
The Retinoic Acid Pathway Therapeutics Market by Route of Administration -
The Retinoic Acid Pathway Therapeutics Market by Distribution Channel -
The Retinoic Acid Pathway Therapeutics Market by End-user -
The Retinoic Acid Pathway Therapeutics Market by Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
